NKGen Biotech, Inc. Common Stock
NKGN
NKGN was delisted on the 4th of March, 2025.
53 hedge funds and large institutions have $143M invested in NKGen Biotech, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 3 closing their positions.
233% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 3
15% more capital invested
Capital invested by funds: $124M → $143M (+$18.9M)
13% more funds holding
Funds holding: 47 → 53 (+6)
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$8.97M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
+$8.78M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$5.23M |
| 4 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$1.79M |
| 5 |
GF
Gabelli Funds
Rye,
New York
|
+$1.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KC
Kepos Capital
New York
|
-$5.1M |
| 2 |
Parallax Volatility Advisers
San Francisco,
California
|
-$1.59M |
| 3 |
CL
CSS LLC
Chicago,
Illinois
|
-$1.29M |
| 4 |
FBCM
Fort Baker Capital Management
Larkspur,
California
|
-$981K |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$318K |
NKGN Hedge Fund Activity: Q3 2022 in Review
53 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in NKGen Biotech, Inc. Common Stock (NKGN) for Q3 2022, worth a combined $143M — up 15% from $124M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new NKGN positions and 3 closed out — a net gain of 7 holders — while 8 added to existing stakes and 8 trimmed.
The largest buyer was Magnetar Financial, adding an estimated $8.97M. The largest seller was Kepos Capital, exiting entirely with an estimated $5.1M sold.
- 53 institutional investors held NKGen Biotech, Inc. Common Stock (NKGN) as of Q3 2022, up from 47 in Q2 2022.
- Funds reported $143M of NKGen Biotech, Inc. Common Stock stock for Q3 2022, up 15% quarter-over-quarter.
- 10 funds opened new NKGen Biotech, Inc. Common Stock positions in Q3 2022 and 3 closed out, a net change of +7 holders.
- The largest NKGen Biotech, Inc. Common Stock buyer in Q3 2022 was Magnetar Financial, an estimated $8.97M added.
- The largest NKGen Biotech, Inc. Common Stock seller in Q3 2022 was Kepos Capital, an estimated $5.1M sold.
Based on aggregated 13F filings for Q3 2022.